Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Canton Strategic Holdings, Inc. filings document the completed name change from Tharimmune, Inc. and ticker change from THAR to CNTN, along with the company's digital asset treasury strategy tied to Canton Coin and the Canton Network. The 8-K record covers material events, amended charter and bylaws, Regulation FD disclosures, full-year operating and financial results, and governance participation through the Canton Foundation.
Its filings also describe capital-structure matters, including registered offerings, at-the-market sales agreements, Form S-3 registration statements, common stock and pre-funded warrant issuance, and related material agreements. Governance disclosures address board composition, bylaws, shareholder matters, and the company's public reporting profile across digital asset treasury and clinical-stage research activities.
Tharimmune, Inc. (THAR) filed a Form 8-K disclosing a corporate governance update. The filing includes a Certificate of Amendment to the Certificate of Incorporation, dated October 10, 2025, furnished as Exhibit 3.1.
The excerpt does not specify the substance of the amendment, and there are no financial results, transactions, or guidance changes disclosed here. The document is signed by Chief Executive Officer Sireesh Appajosyula. Without the amendment’s details, potential effects on shareholders—such as changes to share structure or corporate provisions—are not determinable from this text.
Tharimmune, Inc. reported that stockholders approved several key proposals at a special meeting on October 9, 2025. Investors authorized the board to amend the certificate of incorporation to increase the total number of common shares the company is allowed to issue from 250,000,000 to a range between 500,000,000 and 1,000,000,000, with the exact level and timing left to the board’s discretion any time before October 9, 2026.
Stockholders also approved an amendment to the Amended and Restated 2023 Omnibus Equity Incentive Plan, raising the pool of common shares reserved for equity awards to 2,000,000 shares from 792,602 shares. In addition, they approved a proposal allowing the company to issue securities in one or more non-public offerings consistent with Nasdaq Marketplace Rules 5635(a) and 5635(d), giving the company flexibility to raise capital through private transactions if it chooses.
Tharimmune, Inc. entered into a new agreement that changes how certain existing warrants work. On October 1, 2025, the company amended warrants held by investors that are exercisable for an aggregate 3,408,110 shares of common stock. The amendment makes these warrants immediately exercisable, meaning holders can now convert them into common shares without waiting for any future vesting or timing conditions.
This change does not create new warrants, but updates the terms on existing ones. The eventual impact will depend on how many warrant holders choose to exercise and convert their rights into common stock.
TharImmune, Inc. discloses beneficial ownership for named executives, directors and major shareholders. Chairman Vincent LoPriore holds 1,121,770 shares (18.45%). All named executive officers and directors as a group hold 1,550,334 shares (25.61%). Institutional and large holders listed include Gravitas Capital LP: 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel: 885,644 shares (14.32%), and David Clarke: 783,842 shares (12.79%). Several other holders report positions between about 5% and 8%, and certain individual directors report smaller, de minimis stakes. The table reflects ownership percentages and share counts without forward-looking commentary.
TharImmune, Inc. discloses beneficial ownership for named executives, directors and major shareholders. Chairman Vincent LoPriore holds 1,121,770 shares (18.45%). All named executive officers and directors as a group hold 1,550,334 shares (25.61%). Institutional and large holders listed include Gravitas Capital LP: 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel: 885,644 shares (14.32%), and David Clarke: 783,842 shares (12.79%). Several other holders report positions between about 5% and 8%, and certain individual directors report smaller, de minimis stakes. The table reflects ownership percentages and share counts without forward-looking commentary.
TharImmune, Inc. discloses beneficial ownership for named executives, directors and major shareholders. Chairman Vincent LoPriore holds 1,121,770 shares (18.45%). All named executive officers and directors as a group hold 1,550,334 shares (25.61%). Institutional and large holders listed include Gravitas Capital LP: 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel: 885,644 shares (14.32%), and David Clarke: 783,842 shares (12.79%). Several other holders report positions between about 5% and 8%, and certain individual directors report smaller, de minimis stakes. The table reflects ownership percentages and share counts without forward-looking commentary.
Tharimmune, Inc. preliminary proxy excerpts show ownership stakes for directors, named executive officers and major shareholders. Vincent LoPriore is listed with 1,121,770 shares (18.45%). All named executive officers and directors as a group (7 persons) hold 1,550,334 shares (25.61%). Institutional or large holders shown include Gravitas Capital LP 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel 885,644 shares (14.32%), David Clarke 783,842 shares (12.79%), SDS Capital Partners II, LLC 485,890 shares (8.00%), GSB Holdings, Inc. 418,799 shares (6.99%), and Brightforge Management, LLC 310,910 shares (5.25%). The extract appears to be a partial table of beneficial ownership and signature lines from the preliminary proxy.
Tharimmune, Inc. reported that its Compensation Committee approved higher pay and severance protections for its top two executives. The base salary for CEO Sireesh Appajosyula and Executive Chairman Vincent LoPriore was each increased by $100,000 to $385,000 annually.
The Committee also enhanced their change-of-control benefits. If either executive is terminated within twelve months after a change of control, their severance will rise from two times to three times base salary and target bonus, strengthening their contractual protections in a potential sale or merger scenario.
Tharimmune, Inc. reported that it has regained compliance with Nasdaq listing requirements related to stockholders’ equity. On September 5, 2025, the company received a letter from Nasdaq confirming that, based on a filing showing stockholders’ equity of $6,876,335 as of August 31, 2025, it meets Nasdaq Listing Rule 5550(b)(1). Nasdaq stated that the compliance matter is now closed, meaning Tharimmune’s common stock continues to qualify for listing on The Nasdaq Stock Market.
Tharimmune, Inc. filed Amendment No. 1 to its Form S-3 registration statement, focused on updating back-end disclosure items rather than changing the preliminary prospectus. The amendment revises Item 16 and adds or updates certain exhibits, including legal opinions, consents and previously filed corporate and transaction documents. It also details estimated offering-related expenses, with total fees and costs of $90,819.88, including SEC registration, legal, accounting, printing and miscellaneous expenses, which are to be borne by the selling stockholders (other than underwriting discounts and commissions). The filing restates the company’s indemnification provisions for directors and officers under Delaware law and confirms standard Securities Act undertakings and signature authorizations.
Tharimmune, Inc. filed Amendment No. 1 to its Form S-3 registration statement, focused on updating back-end disclosure items rather than changing the preliminary prospectus. The amendment revises Item 16 and adds or updates certain exhibits, including legal opinions, consents and previously filed corporate and transaction documents. It also details estimated offering-related expenses, with total fees and costs of $90,819.88, including SEC registration, legal, accounting, printing and miscellaneous expenses, which are to be borne by the selling stockholders (other than underwriting discounts and commissions). The filing restates the company’s indemnification provisions for directors and officers under Delaware law and confirms standard Securities Act undertakings and signature authorizations.
Tharimmune, Inc. filed Amendment No. 1 to its Form S-3 registration statement, focused on updating back-end disclosure items rather than changing the preliminary prospectus. The amendment revises Item 16 and adds or updates certain exhibits, including legal opinions, consents and previously filed corporate and transaction documents. It also details estimated offering-related expenses, with total fees and costs of $90,819.88, including SEC registration, legal, accounting, printing and miscellaneous expenses, which are to be borne by the selling stockholders (other than underwriting discounts and commissions). The filing restates the company’s indemnification provisions for directors and officers under Delaware law and confirms standard Securities Act undertakings and signature authorizations.
Nancy Davis Rickel, a director of Tharimmune, Inc. (THAR), filed an initial Form 3 disclosing ownership of 50,000 stock options granted on 08/04/2025. The options are exercisable into common stock at an exercise price of $1.33 per share, with 25,000 shares vesting immediately and 25,000 vesting on 08/04/2026. The filing is signed by Ms. Rickel on 08/29/2025 and was filed as an individual Form 3.
Tharimmune, Inc. is offering securities that raise approximately $4,814,996 in gross proceeds, with placement agent fees of $535,000 (10% of gross proceeds). The prospectus supplement shows common stock outstanding rising from 5,691,444 shares before the offering to 6,880,332 shares after the offering, and a pro forma net tangible book value per share of $0.09 as of June 30, 2025. Net proceeds are intended for working capital and general corporate purposes. The company states it has never paid cash dividends and does not anticipate doing so. Tharimmune’s Quatramer platform is described as a proprietary tumor-targeting approach to deliver drugs to the tumor microenvironment. The filing also discloses dependence on sole-source suppliers for certain ingredients and highlights that investing involves a high degree of risk.